Discontinuation of Oral Anticoagulation After Successful Atrial Fibrillation Ablation – Are We Ready to Change Clinical Practice in 2026?

08 May 2026 : Review article

Karol Momot

^{ABCDEFG 1,2}, Stanisław Surma

^{ABEF 3}, Kamil Krauz

^{DEF 1,4*}, Michał Pruc

^{BEF 5}, Łukasz Szarpak

^{DEF 5,6}, Dariusz Rodkiewicz

^{EF 2}, Małgorzata Buksińska-Lisik

^{EF 2}, Artur Mamcarz

^{AE 2}

DOI: 10.12659/MSM.952757

Med Sci Monit 2026; 32:e952757

Authors information Article notes Copyright and License information

Introduction Evidence Prior to Randomized Controlled Trials Data From Prospective Randomized Controlled Trials Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 1 Comparison of randomized controlled trials.

	OCEAN	ALONE-AF
Study design
Study population
Inclusion criteria
Exclusion criteria
Intervention arm	Aspirin (70 to 120 mg daily)	Discontinuation of all OAC/antiplatelet therapy (no aspirin and no OAC)
Control arm	Rivaroxaban (15 mg daily)	Continuation of either apixaban 5 mg twice daily or rivaroxaban 20 mg once daily
Primary endpoint	Composite:	Composite:
Secondary endpoints
Rhythm monitoring method
Follow-up duration
AF – atrial fibrillation; CA – catheter ablation; DBP – diastolic blood pressure; ECG – electrocardiogram; ILR – implantable loop recorder; MRI – magnetic resonance imaging; OAC – oral anticoagulation; SBP – systolic blood pressure; TIA – transient ischemic attack.

Back to the Article